KR20240026526A - Ras를 억제하는 방법 - Google Patents

Ras를 억제하는 방법 Download PDF

Info

Publication number
KR20240026526A
KR20240026526A KR1020237044138A KR20237044138A KR20240026526A KR 20240026526 A KR20240026526 A KR 20240026526A KR 1020237044138 A KR1020237044138 A KR 1020237044138A KR 20237044138 A KR20237044138 A KR 20237044138A KR 20240026526 A KR20240026526 A KR 20240026526A
Authority
KR
South Korea
Prior art keywords
optionally substituted
membered
alkyl
ras
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237044138A
Other languages
English (en)
Korean (ko)
Inventor
카일 시몬
Original Assignee
레볼루션 메디슨즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 레볼루션 메디슨즈, 인크. filed Critical 레볼루션 메디슨즈, 인크.
Publication of KR20240026526A publication Critical patent/KR20240026526A/ko
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/504Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020237044138A 2021-05-25 2022-05-25 Ras를 억제하는 방법 Pending KR20240026526A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192837P 2021-05-25 2021-05-25
US63/192,837 2021-05-25
PCT/US2022/030823 WO2022251292A1 (en) 2021-05-25 2022-05-25 Methods for inhibiting ras

Publications (1)

Publication Number Publication Date
KR20240026526A true KR20240026526A (ko) 2024-02-28

Family

ID=82115695

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237044138A Pending KR20240026526A (ko) 2021-05-25 2022-05-25 Ras를 억제하는 방법

Country Status (11)

Country Link
US (1) US20240277796A1 (https=)
EP (1) EP4346898A1 (https=)
JP (1) JP2024521774A (https=)
KR (1) KR20240026526A (https=)
CN (2) CN118557730A (https=)
AU (1) AU2022281343A1 (https=)
CA (1) CA3219533A1 (https=)
IL (1) IL308771A (https=)
MX (1) MX2023013912A (https=)
TW (1) TW202313631A (https=)
WO (1) WO2022251292A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
AU2022268962A1 (en) 2021-05-05 2023-12-14 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
AR127308A1 (es) * 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
CN118922423A (zh) * 2022-01-10 2024-11-08 锐新医药公司 Ras抑制剂
CN119301132A (zh) * 2022-06-01 2025-01-10 豪夫迈·罗氏有限公司 用于治疗癌症的卤代吲哚大环化合物
CN119522225A (zh) 2022-09-29 2025-02-25 广州嘉越医药科技有限公司 大环衍生物及其应用
CR20250329A (es) 2023-02-14 2025-09-12 Hoffmann La Roche Compuestos tricíclicos para el tratamiento del cáncer
EP4687905A1 (en) * 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
TW202446387A (zh) * 2023-04-06 2024-12-01 瑞士商赫孚孟拉羅股份公司 用於治療癌症之三環化合物
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025019318A2 (en) * 2023-07-14 2025-01-23 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2025162395A1 (zh) * 2024-02-01 2025-08-07 山东先声生物制药有限公司 吲哚衍生物作为ras抑制剂及其应用
CN119431325A (zh) * 2024-10-31 2025-02-14 诚达药业股份有限公司 一种3-(1h-吡唑-1-基)氮杂环丁烷类化合物及其合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210116479A (ko) 2018-12-21 2021-09-27 레볼루션 메디슨즈, 인크. 공동 결합에 참여하는 화합물 및 그의 용도
DE102019122206B4 (de) 2019-08-19 2021-07-08 Webasto SE Dachmodul zur Bildung eines Fahrzeugdachs mit Umfeldsensor
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
CN120699039A (zh) 2019-11-04 2025-09-26 锐新医药公司 Ras抑制剂
WO2021091956A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.

Also Published As

Publication number Publication date
CN117715658A (zh) 2024-03-15
TW202313631A (zh) 2023-04-01
JP2024521774A (ja) 2024-06-04
MX2023013912A (es) 2024-02-12
US20240277796A1 (en) 2024-08-22
IL308771A (en) 2024-01-01
CA3219533A1 (en) 2022-12-01
CN118557730A (zh) 2024-08-30
WO2022251292A1 (en) 2022-12-01
EP4346898A1 (en) 2024-04-10
AU2022281343A1 (en) 2023-11-30

Similar Documents

Publication Publication Date Title
KR20240026526A (ko) Ras를 억제하는 방법
AU2022360536B2 (en) Ras inhibitors
KR20240004960A (ko) Ras 억제제
CN118852330A (zh) 用于治疗癌症的ras抑制剂
CN115873020A (zh) Ras抑制剂
KR20240132492A (ko) Ras 억제제
EP4720072A2 (en) Ras inhibitors
KR20220109407A (ko) Ras 억제제
CN113498342A (zh) 参与协同结合的化合物和其用途
KR20260005904A (ko) 매크로사이클릭 ras 억제제
KR20260007210A (ko) 매크로사이클릭 ras 억제제
CN115916194A (zh) 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
HK40076306A (en) Ras inhibitors
WO2025171296A1 (en) Ras inhibitors
HK40076319A (en) Ras inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231220

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250523

Comment text: Request for Examination of Application